vs

Side-by-side financial comparison of Digimarc CORP (DMRC) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Digimarc CORP is the larger business by last-quarter revenue ($8.9M vs $6.6M, roughly 1.3× Lineage Cell Therapeutics, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -47.2%, a 60.1% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 2.9%). Digimarc CORP produced more free cash flow last quarter ($895.0K vs $-5.3M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -5.3%).

Digimarc Corporation is a provider of enterprise software and services. The company's software, which includes digital identifiers, is designed to address counterfeiting, product authenticity, recycling accuracy, and supply chain traceability. Digimarc products are created for multiple industries such as apparel, consumer packaged goods, health and beauty, and automotive.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

DMRC vs LCTX — Head-to-Head

Bigger by revenue
DMRC
DMRC
1.3× larger
DMRC
$8.9M
$6.6M
LCTX
Growing faster (revenue YoY)
LCTX
LCTX
+127.5% gap
LCTX
130.4%
2.9%
DMRC
Higher net margin
LCTX
LCTX
60.1% more per $
LCTX
12.9%
-47.2%
DMRC
More free cash flow
DMRC
DMRC
$6.2M more FCF
DMRC
$895.0K
$-5.3M
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-5.3%
DMRC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DMRC
DMRC
LCTX
LCTX
Revenue
$8.9M
$6.6M
Net Profit
$-4.2M
$851.0K
Gross Margin
63.5%
Operating Margin
-48.2%
-99.1%
Net Margin
-47.2%
12.9%
Revenue YoY
2.9%
130.4%
Net Profit YoY
51.4%
126.0%
EPS (diluted)
$-0.18
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMRC
DMRC
LCTX
LCTX
Q4 25
$8.9M
$6.6M
Q3 25
$7.6M
$3.7M
Q2 25
$8.0M
$2.8M
Q1 25
$9.4M
$1.5M
Q4 24
$8.7M
$2.9M
Q3 24
$9.4M
$3.8M
Q2 24
$10.4M
$1.4M
Q1 24
$9.9M
$1.4M
Net Profit
DMRC
DMRC
LCTX
LCTX
Q4 25
$-4.2M
$851.0K
Q3 25
$-8.2M
$-29.8M
Q2 25
$-8.2M
$-30.5M
Q1 25
$-11.7M
$-4.1M
Q4 24
$-8.6M
$-3.3M
Q3 24
$-10.8M
$-3.0M
Q2 24
$-9.3M
$-5.8M
Q1 24
$-10.3M
$-6.5M
Gross Margin
DMRC
DMRC
LCTX
LCTX
Q4 25
63.5%
Q3 25
58.3%
Q2 25
58.8%
Q1 25
65.0%
97.6%
Q4 24
60.8%
94.6%
Q3 24
62.4%
99.0%
Q2 24
66.1%
96.9%
Q1 24
62.5%
93.2%
Operating Margin
DMRC
DMRC
LCTX
LCTX
Q4 25
-48.2%
-99.1%
Q3 25
-109.7%
-102.9%
Q2 25
-105.2%
-715.4%
Q1 25
-128.9%
-433.1%
Q4 24
-105.1%
-178.2%
Q3 24
-120.4%
-101.6%
Q2 24
-96.2%
-416.7%
Q1 24
-109.2%
-461.3%
Net Margin
DMRC
DMRC
LCTX
LCTX
Q4 25
-47.2%
12.9%
Q3 25
-106.9%
-809.0%
Q2 25
-102.6%
-1101.8%
Q1 25
-125.2%
-275.6%
Q4 24
-99.9%
-114.1%
Q3 24
-113.9%
-80.3%
Q2 24
-89.3%
-409.1%
Q1 24
-104.0%
-453.0%
EPS (diluted)
DMRC
DMRC
LCTX
LCTX
Q4 25
$-0.18
$0.00
Q3 25
$-0.38
$-0.13
Q2 25
$-0.38
$-0.13
Q1 25
$-0.55
$-0.02
Q4 24
$-0.40
$0.00
Q3 24
$-0.50
$-0.02
Q2 24
$-0.43
$-0.03
Q1 24
$-0.50
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMRC
DMRC
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$12.9M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$40.2M
$44.5M
Total Assets
$53.0M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMRC
DMRC
LCTX
LCTX
Q4 25
$12.9M
$55.8M
Q3 25
$12.6M
$40.5M
Q2 25
$16.1M
$42.3M
Q1 25
$21.6M
$47.9M
Q4 24
$28.7M
$47.8M
Q3 24
$33.7M
$32.7M
Q2 24
$41.5M
$38.5M
Q1 24
$48.9M
$43.6M
Stockholders' Equity
DMRC
DMRC
LCTX
LCTX
Q4 25
$40.2M
$44.5M
Q3 25
$41.4M
$22.0M
Q2 25
$46.5M
$48.4M
Q1 25
$50.0M
$79.0M
Q4 24
$61.4M
$78.4M
Q3 24
$70.2M
$66.2M
Q2 24
$77.2M
$68.3M
Q1 24
$84.5M
$72.4M
Total Assets
DMRC
DMRC
LCTX
LCTX
Q4 25
$53.0M
$112.6M
Q3 25
$55.4M
$89.6M
Q2 25
$60.7M
$90.8M
Q1 25
$66.5M
$111.8M
Q4 24
$75.8M
$113.2M
Q3 24
$85.0M
$96.6M
Q2 24
$93.4M
$102.8M
Q1 24
$99.7M
$108.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMRC
DMRC
LCTX
LCTX
Operating Cash FlowLast quarter
$991.0K
$-4.9M
Free Cash FlowOCF − Capex
$895.0K
$-5.3M
FCF MarginFCF / Revenue
10.0%
-79.9%
Capex IntensityCapex / Revenue
1.1%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-12.3M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMRC
DMRC
LCTX
LCTX
Q4 25
$991.0K
$-4.9M
Q3 25
$-2.6M
$-3.6M
Q2 25
$-4.7M
$-5.5M
Q1 25
$-5.5M
$-4.9M
Q4 24
$-4.2M
$-6.3M
Q3 24
$-7.1M
$-5.8M
Q2 24
$-6.8M
$-5.2M
Q1 24
$-8.4M
$-5.8M
Free Cash Flow
DMRC
DMRC
LCTX
LCTX
Q4 25
$895.0K
$-5.3M
Q3 25
$-2.8M
$-3.6M
Q2 25
$-4.9M
$-5.6M
Q1 25
$-5.5M
$-5.0M
Q4 24
$-4.2M
$-6.7M
Q3 24
$-7.2M
$-5.9M
Q2 24
$-6.9M
$-5.2M
Q1 24
$-8.5M
$-5.8M
FCF Margin
DMRC
DMRC
LCTX
LCTX
Q4 25
10.0%
-79.9%
Q3 25
-36.9%
-98.6%
Q2 25
-61.0%
-200.8%
Q1 25
-59.1%
-331.8%
Q4 24
-49.1%
-234.0%
Q3 24
-75.7%
-156.1%
Q2 24
-66.1%
-371.2%
Q1 24
-85.8%
-403.1%
Capex Intensity
DMRC
DMRC
LCTX
LCTX
Q4 25
1.1%
6.0%
Q3 25
2.9%
0.3%
Q2 25
2.5%
0.5%
Q1 25
0.6%
6.5%
Q4 24
0.2%
12.7%
Q3 24
0.7%
3.0%
Q2 24
0.3%
3.6%
Q1 24
1.1%
2.6%
Cash Conversion
DMRC
DMRC
LCTX
LCTX
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMRC
DMRC

Subscription$5.3M60%
The Government$3.6M41%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons